chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report was received from a pharmacist and refers to a currently 71 year old male patient. The patient's concurrent conditions included diabetes and hypertension. The patient's concomitant therapies included atorvastatin, metformin, lisinopril (manufacturer unknown), hydrochlorothiazide (manufacturer unknown) and clopidogrel. The patient did not have any drug reactions or allergies. In October 2015, the patient was vaccinated with a dose of an unspecified influenza virus vaccine (unspecified) and an unspecified time after receiving the flu vaccine, the patient "got sick". On 01-FEB-2016, the patient was vaccinated with a dose of ZOSTAVAX (lot # L037797, expiration date: 30-DEC-2016, 0.65 ml, subcutaneously). On 15-FEB-2016, the patient called the pharmacy stating he developed "flu-like symptoms, a fever and lesions all over his body" an unspecified time after receiving ZOSTAVAX. On an unspecified date, the patient was seen by an unspecified physician in regards to the reaction and was prescribed unspecified antifungal cream, unspecified antifungal shampoo and an unspecified antifungal tablet as a treatment. The pharmacist stated the patient picked up all the antifungals on 15-FEB-2016. The patient was again seen by an unspecified physician in regards to the reaction and was prescribed triamcinolone and mupirocin. The pharmacist stated that the patient picked up the triamcinolone and mupirocin on 18-FEB-2016. The pharmacist stated the patient was seen at the pharmacy on 14-APR-2016, and said he was admitted to an unspecified hospital due to the reaction on an unspecified date in 2016 and was discharged on an unspecified date in 2016. No laboratory tests were performed. The patient was claiming it caused significant disability because he missed a lot of work. The outcome of flu-like symptoms, fever and lesions all over the patient's body was reported as not recovered. The relatedness between the events and ZOSTAVAX was not reported. Additional information has been requested.
~2:00PM on 10/11/10, patient's arm began feeling sore.  Later she began feeling fatigued with muscle aches.  She stated that evening she began to run a fever of 99.2 to 99.7.  She stated she could not sleep and around midnight she began having auditory and visual hallucinations of people she knew being all around her.  She stated she visited with them all night.  She stated she could not pick up any objects.  She stated colors and objects tended to "blend into one another".  The morning of October 12 she stated she could not operate a telephone.  She reported to work around 5:00pm.  I ran into her in the hallway.  She looked pale with dark circles under her eye.  Her speech was pressured and her thoughts tended to race from one subject to another.  She just told me she had been running a slight temp and had flu-like symptoms.  I saw patient on Wednesday, October 13 around 1:00PM.  I stopped by her office to see if she was feeling any better.  She began to tell me of the events of the previous 2 days after receiving the vaccine.  I told her I thought she could possibly be have an adverse reaction to the vaccine.  I called VAERS and the person I spoke with confirmed this was an adverse event that needed reporting.  She told me she would send the forms.
Systemic: Rash (other than injection site), Systemic: Fever, Systemic: Generalized Body Aches; symptoms lasted 1 day
numbness and tingling on right side of face and in right arm and shoulder.; numbness and tingling on right side of face and in right arm and shoulder.; tingling on right side of face and in right arm and shoulder.; swollen right eye; nausea; severe headache; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old non-pregnant female patient received (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EH6198; DOSE NUMBER: 1) via an unspecified route of administration on her left arm on 06Mar2021, as single dose for Covid-19 vaccination (at the age of 46 years). Medical history and concomitant medications were not reported. No other vaccines were administered within four weeks. The patient has allergy to penicillin. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 12Mar2021 at 20:00 (reported as 6 days post-vaccination), the patient developed nausea, swollen right eye and severe headache that had persisted for several days then. On 15Mar2021 (reported as day 3), the patient developed numbness and tingling on right side of face and in right arm and shoulder. The patient underwent Computed Tomogram (CT) scan and Magnetic Resonance Imaging (MRI) (dates and results not reported). The patient received treatment for the events (treatment details not reported). She was taken to emergency room due to the events. The outcome of all the events was unknown. No follow-up attempts are possible. No further information is expected.
Nine days post vax, the pt experienced 30+ lesions throughout body and a temperature of 100.8 degrees F. He was treated with acetaminophen.  Subsequently, he recovered. No further information is available.
blood clots on lungs  2 days in hospital   on blood thinner for the last 10 days
Fatigue, Exhaustion, Brain Fog, Insomnia, faulty temperature regulation, body chills/shivers/tingling
Dizziness and nausea. It started 48 hours after my first dose of the vaccine and still is a problem more than 72 hours later.
RECEIVED LESS THAN 0.5ML (APPROXIMATELY AROUND 0.3ML) OF VACCINE AS A BOOSTER DOSE; OFF LABEL USE; This spontaneous report received from a health care professional concerned a 43 year old   female. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. On an unspecified date, the patient was previously treated with covid-19 vaccine ad26.cov2.s from unspecified manufacturer (suspension for injection, route of admin not reported, batch number: Unknown expiry: Unknown) dose was not reported (dose number in series  1), 1 in total administered for prophylactic vaccination. It was unknown whether patient had any adverse event following vaccination with covid-19 vaccine ad26.cov2.s. The patient received additional dose of covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 213D21A, expiry: 11-APR-2022)  approximately around 0.3mL (dose number in series  2), 1 in total, administered on 01-DEC-2021 for prophylactic vaccination on left arm. No concomitant medications were reported.  On 01-DEC-2021, following vaccination with covid-19 vaccine ad26.cov2.s, the reporter mentioned that patient received less than 0.5ml of the vaccine as a booster dose approximately around 0.3mL of dose (vaccine underdose and off label use). The health care professional who administered the vaccine mentioned that the patient was injected 0.5mL but the reporter mentioned that the calculation (she arrived at that by dividing 2.5mL by 5 doses) did prove that the patient received approximately around 0.3mL only.(dose number in series  2) The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the received less than 0.5ml (approximately around 0.3ml) of vaccine as a booster dose and off label use was not reported. This report was non-serious. This case, from the same reporter is linked to 20211209679, 20211209706, 20211209740, 20211209782, 20211209816, 20211209843, 20211209880, 20211209912, 20211209921, 20211210019, 20211210058, 20211209551, 20211210067, 20211209976, 20211210160, 20211210588, 20211210197, 20211210112, 20211209775, 20211210610, 20211209798, 20211209874, 20211209884, 20211210133, 20211210549, 20211210106, 20211210107, 20211210141, 20211210143, 20211210159, 20211210165, 20211210180, 20211210334, 20211210350, 20211210385, 20211210408, 20211210585, 20211210590, 20211210662, 20211210670, 20211210684, 20211210733, 20211210824, 20211212082, 20211212088 and 20211210555.
I just dont feel well.; Headaches; brain fog continuing; This is a spontaneous report from a contactable nurse, the patient. A 52-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration on 02Apr2021 at 14:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19 on an unknown date in Jul2020. The patient had no known allergies to medications, food or other products. The patient did not receive any medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6204) via an unspecified route of administration in right arm on 12Mar2021 at 14:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 01:00, the patient did not feel well, headaches and brain fog continued (at the time of this report). The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events did not feel well, headaches and brain fog continued were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Red marks under arm; Had trouble with some of joints / had pain in joints; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (Red marks under arm) and ARTHRALGIA (Had trouble with some of joints / had pain in joints) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    No Medical History information was reported.   On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate Free. On an unknown date, ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to Citrate Free. On an unknown date, the patient experienced ERYTHEMA (Red marks under arm) and ARTHRALGIA (Had trouble with some of joints / had pain in joints). At the time of the report, ERYTHEMA (Red marks under arm) and ARTHRALGIA (Had trouble with some of joints / had pain in joints) had not resolved.            No concomitant medications were reported.  It was unknown if the patient was enrolled in a COVID-19 vaccine trial.  No treatment medications were reported.
lightheadedness for 2 hours after vaccine; Flushing and tongue numbness within 2-3 minutes of vaccine administration; Flushing and tongue numbness within 2-3 minutes of vaccine administration; This is a spontaneous report from a contactable Physician (patient)  A 42-year-old female patient received,at hospital, the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) intramuscular on arm left on 17Dec2020 (reported as at 01:15 PM)  at a single dose for COVID-19 immunization .Medical history prior history of allergies requiring allergy shots, GERD , GERD and Sulfa and environmental/food allergies , food allergy .Concomitant medication included ibuprofen and cetirizine hydrochloride (ZYRTEC ). No Covid prior vaccination and no covid test vaccination provided . On17Dec2020 at 01:15 PM , the patient experienced Flushing and tongue numbness within 2-3 minutes of vaccine administration and lightheadedness for 2 hours after vaccine.All events were reported as non-serious. Patient received treatment with Benadryl 25 mg PO (per oral).The outcome of the events was recovered in Dec2020. Information on the lot/batch number has been requested.
red, painful, induration (4.5 cm x 5.5 cm) on (R) upper outer arm at site of vaccine, evolved over 48 hr. Tx: CEPHALEXIN 25015 2 1/2 BP po E12 deg x 1 od.
Booster; chronic emphysema; oxygen level went low; This is a spontaneous report based on information received by Pfizer from a non-contactable consumer (patient).  The 57-year-old non-pregnant female patient received bnt162b2(Pfizer Covid-19 medication), dose 3 via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as dose 3 (booster), single for covid-19 immunisation; fluticasone furoate, umeclidinium bromide, vilanterol trifenatate (TRELEGY ELLIPTA, Expiry Date: Feb2023), via an unspecified route of administration from 2020 and ongoing, at unspecified dose for an unspecified indication.  The patient medical history and concomitant medications were not reported. Historical vaccine included dose 1 and dose 2 both BNT162B2 on an unspecified date for COVID-19 immunization.  The patient experienced chronic emphysema and oxygen level went low on 01Oct2021 which led to hospitalization. Patient was on a BIPAP machine in the hospital. Patient went in 01Oct2021 and was released 08Oct2021.Patient has been on fluticasone furoate, umeclidinium bromide, vilanterol trifenatate for a year. Patient received the pfizer booster shot and she felt like that had something to do with it. The action taken in response to the events for fluticasone furoate, umeclidinium bromide, vilanterol trifenatate was unknown. Outcome of events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
hot flashes hotter,coldness colder, response to stimuli greater; Anxiety; Forgetfulness; Shortness of breath; Joint Inflammation; Blood pressure increased; Mild headaches; muscle pain; shaky; muscle weakness/ joint weakness; This spontaneous case was reported by a consumer and describes the occurrence of NERVOUSNESS (shaky), MUSCULAR WEAKNESS (muscle weakness/ joint weakness), SENSITIVITY TO WEATHER CHANGE (hot flashes hotter,coldness colder, response to stimuli greater), ANXIETY (Anxiety) and MEMORY IMPAIRMENT (Forgetfulness) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 010A21A and 48B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Asthma (shortness of breath) since 2002, Arthritis (increase in joint inflammation and pain), Environmental allergy, Allergic reaction to antibiotics (allergic to doxycycline and bactrim) and Drug allergy (allergic to Prilosec , prometrium). Concomitant products included FLUTICASONE PROPIONATE (FLOVENT) for Asthma, FAMOTIDINE for GERD, VITAMIN D NOS, ASCORBIC ACID (VITAMIN C ACID), ZINC and CALCIUM for an unknown indication.   On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 04-Mar-2021, the patient experienced NERVOUSNESS (shaky), MUSCULAR WEAKNESS (muscle weakness/ joint weakness), HEADACHE (Mild headaches) and MYALGIA (muscle pain). On an unknown date, the patient experienced SENSITIVITY TO WEATHER CHANGE (hot flashes hotter,coldness colder, response to stimuli greater), ANXIETY (Anxiety), MEMORY IMPAIRMENT (Forgetfulness), DYSPNOEA (Shortness of breath), ARTHRITIS (Joint Inflammation) and BLOOD PRESSURE INCREASED (Blood pressure increased). On 05-Mar-2021, NERVOUSNESS (shaky) had resolved. On 18-Mar-2021, HEADACHE (Mild headaches) and MYALGIA (muscle pain) had resolved. At the time of the report, MUSCULAR WEAKNESS (muscle weakness/ joint weakness), SENSITIVITY TO WEATHER CHANGE (hot flashes hotter,coldness colder, response to stimuli greater), ANXIETY (Anxiety), MEMORY IMPAIRMENT (Forgetfulness), DYSPNOEA (Shortness of breath), ARTHRITIS (Joint Inflammation) and BLOOD PRESSURE INCREASED (Blood pressure increased) had not resolved.            Most recent FOLLOW-UP information incorporated above includes: On 26-May-2021: Follow-up received. Patient information , Second dose details , Concomitant medications and events were added
Heart started to race around 11:30pm on 6/12/2021. I felt fluttering sensation. I took ECG on my watch which shows the rhythm. My normal heart rate is around 60 bpm, but while I was doing nothing/laying in bed--it shot up to 90 bpms. I probably experienced this sensation for an hour, and then experienced fluttering sensation for the next 3 days. I called my doctor to see if I needed to go to the ER, but they said I should continue to monitor, avoid stimulants, and come to ER if I experienced worsening symptoms.  I had a follow up appointment with my doctor later that week, and we decided I should schedule to wear a holter monitor.
This spontaneous report as received from a medical assistant refers to a 12 month old infant, gender was not reported. On 21-AUG-2014, the patient was vaccinated with VAQTA lot # K007791, expiration date 22-AUG-2014 (dose, strength, route and frequency were not reported). Patient received improperly stored VAQTA exposed to 49F for 35 minutes. No adverse effects were reported. This is one of several reports from the same source. Additional information has been requested.
Developed hives and scratch like rash all over the body. It would come and go and move. Hot to the touch and itchy. Went to the doctor and began Zyrtec. As of now have had hives for 15 days.
After my 2nd shot I had tingling in my thumb; This is a spontaneous report from a contactable consumer (reporting herself). This 43-Year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot Number: EL3302), via an unspecified route of administration in right arm on 03Feb2021 at 10:00 (age at the time of vaccination was 43 years old) as single dose for COVID-19 immunization. The patient's medical history included asthma. The patient had unspecified allergies. The patient's concomitant medications were not reported. The patient did not receive any other vaccine in four weeks of COVID vaccination. The patient did not experience COVID-19 prior to vaccination. The patient received other unspecified medication in two weeks of vaccination. Previously, the patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Batch/Lot Number: EL0142), via an unspecified route of administration in right arm on 13Jan2021 at 10:00 as single dose for COVID-19 immunization. On 03Feb2021 at 10:00, After the second shot, the patient had tingling in her thumb and on her first two fingers (like finger fell asleep) and had very little feeling. This was lasted about for 2 and half hours. The patient did not received any treatment for the event. On 26Feb2021, the patient tested negative for COVID test. On 04Mar2021, the patient again tested for COVID and the result was pending. The outcome of the event was resolved.  No follow-ups are possible. No further information is required.
Fever; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PYREXIA (Fever). At the time of the report, PYREXIA (Fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Concomitant medications were not provided by reporter. Treatment information was not provided by reporter.   This case was linked to MOD-2021-317898, MOD-2021-317907 (Patient Link).   Reporter did not allow further contact
Dizziness immediately after vaccine- remitted within 5 minutes.  Occasional heart palpitations day of and day after vaccine. But the worst is that over 2 weeks later, my left upper arm has incredible pain and has weakened strength.  Pharmacist possibly hit a bursa sac.
Patient states she received both vaccines through Pharmacy on left arm on Friday (01/13/23). Started noticing a small red, itchy rash on Saturday, which has since grown in size approximately 10cm by 7cm in size over the last few days, extending on her upper forearm. Reports rash is itchy and red. Pt states color has reduced to pink since yesterday.  Patient being treated with topical corticosteroids and has an appointment with her PCP later this week.
Parent phoned me at home to describe area of erythema and heat approx 4x5cm at site of injection extending distally. Pt described as active, afebrile. I saw the child 11/9/02 and noted redness, etc. Child w/o other symptoms.
Janssen -COVID 19- EUA    04-06-21 Adverse Event #1  Approximately 3 minutes following vaccination Pt had seizure. Personnel on scene assisted her to the ground and protected her head. No injuries from event. Pt assessed by Team 1 crew member, then turned over to ALS Medic unit.
This is a cluster of 2 patients who experienced adverse events following administration of FLUZONE HIGH-DOSE; lot number UH436AB. The event for the other patient was captured in case number 2011-10928. Initial report was received from a healthcare professional, on 08 November 2011. A 70-year-old female patient had received an Intramuscular (IM) injection of FLUZONE HIGH-DOSE; lot number UH436AB on 18 October 2011. On an unspecified date, the patients arm swelled up from the shoulder to the elbow; the area was red and painful. The patient received corrected treatment with pain medications and ice packs. No further information was available at the time of the report. The patient outcome was reported as resolved/recovered. Follow-up information was received from a healthcare professional on 17 January 2012. The patient received an Intramuscular injection of FLUZONE HIGH-DOSE in upper arm. The patient was not seen in follow-up for the symptoms described and no additional corrective treatment provided. Documents held by sender: none.
Pt broke out with 2 - 5 mm wheals around injection site. Treated with Benadryl and ice. Stayed 20 minutes post incident.
fever, joint and muscle pain, nausea, headache. Took Tylenol which helped with the inflammation but not the fever.
This spontaneous report as received from a physician via company representative, and refers to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant therapies were not reported. On 13-MAR-2014, the patient was vaccinated with a dose of improperly stored PNEUMOVAX 23 "10 Single dose 0.5mLVIs 10SDV" with lot number J009689 with expiration date of 29-JAN-2015 (route of administration and anatomical location were not reported), which was stored at 34 Fahrenheit (F) Degrees (1.111111111 Celsius) for a total of 144 hours. The vaccine status was reported as "in excursion". The vaccine storage criteria and the vaccine excursion were reported as "Refrigerator(R)". No adverse effect were reported and nor product quality complaint was involved. This is one of several cases received from the same reporter. Additional information has been requested.